Switch theme
Sign up to access all valuation multiples
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
2020
1.1K+
LTM Revenue $425M
LTM EBITDA $97.2M
$552M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CureVac has a last 12-month revenue (LTM) of $425M and a last 12-month EBITDA of $97.2M.
In the most recent fiscal year, CureVac achieved revenue of $535M and an EBITDA of $210M.
CureVac expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CureVac valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $425M | XXX | $535M | XXX | XXX | XXX |
| Gross Profit | $351M | XXX | $429M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $97.2M | XXX | $210M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 39% | XXX | XXX | XXX |
| EBIT | $73.5M | XXX | $178M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $73.0M | XXX | $162M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CureVac's stock price is $4.
CureVac has current market cap of $1.0B, and EV of $552M.
See CureVac trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $552M | $1.0B | XXX | XXX | XXX | XXX | $0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CureVac has market cap of $1.0B and EV of $552M.
CureVac's trades at 1.0x EV/Revenue multiple, and 2.6x EV/EBITDA.
Equity research analysts estimate CureVac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CureVac has a P/E ratio of 15.5x.
See valuation multiples for CureVac and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $552M | XXX | $552M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBIT | 8.4x | XXX | 3.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.5x | XXX | 6.2x | XXX | XXX | XXX |
| EV/FCF | 9.4x | XXX | 6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCureVac's last 12 month revenue growth is -76%
CureVac's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
CureVac's rule of 40 is -512% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CureVac's rule of X is -168% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CureVac and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -76% | XXX | -58% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | -219% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -512% | XXX | -37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -168% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CureVac acquired XXX companies to date.
Last acquisition by CureVac was XXXXXXXX, XXXXX XXXXX XXXXXX . CureVac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CureVac founded? | CureVac was founded in 2020. |
| Where is CureVac headquartered? | CureVac is headquartered in United States of America. |
| How many employees does CureVac have? | As of today, CureVac has 1.1K+ employees. |
| Who is the CEO of CureVac? | CureVac's CEO is Dr. Alexander Zehnder, M.B.A.,M.D.. |
| Is CureVac publicy listed? | Yes, CureVac is a public company listed on NAS. |
| What is the stock symbol of CureVac? | CureVac trades under CVAC ticker. |
| When did CureVac go public? | CureVac went public in 2020. |
| Who are competitors of CureVac? | Similar companies to CureVac include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of CureVac? | CureVac's current market cap is $1.0B |
| What is the current revenue of CureVac? | CureVac's last 12 months revenue is $425M. |
| What is the current revenue growth of CureVac? | CureVac revenue growth (NTM/LTM) is -76%. |
| What is the current EV/Revenue multiple of CureVac? | Current revenue multiple of CureVac is 1.5x. |
| Is CureVac profitable? | Yes, CureVac is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CureVac? | CureVac's last 12 months EBITDA is $97.2M. |
| What is CureVac's EBITDA margin? | CureVac's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of CureVac? | Current EBITDA multiple of CureVac is 6.4x. |
| What is the current FCF of CureVac? | CureVac's last 12 months FCF is $65.9M. |
| What is CureVac's FCF margin? | CureVac's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of CureVac? | Current FCF multiple of CureVac is 9.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
